 | | Vol. 10.36 – 13 September, 2022 |
| |
|
|
| Investigators performed single-cell transcriptome sequencing of 105 pretreatment and post-treatment peripheral blood mononuclear cell samples, and infusion products collected from 32 individuals with large B cell lymphoma treated with either of two CD19 CAR-T products: axicabtagene ciloleucel or tisagenlecleucel.
[Nature Medicine] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Single-cell proteomic profiling of circulating CAR T cells in 32 patients treated with CD19-CAR identified that CD4+Helios+ CAR T cells on day seven after infusion were associated with progressive disease and less severe neurotoxicity.
[Nature Medicine] |
|
|
|
| The authors conducted a clinical trial in stable liver recipients two to six years post-transplant to determine the capacity of low dose interleukin-2 to suppress allospecific immune responses and allow for the complete discontinuation of maintenance immunosuppression.
[Journal of Hepatology] |
|
|
|
| A methoxy poly(ethylene glycol) (mPEG)-masked CD44×PD-L1/CD3 trispecific T cell nanoengager loaded with the STING agonist c-di-AMP for the treatment of triple-negative breast cancer (TNBC) was rationally designed.
[Advanced Science] |
|
|
|
| Scientists used single-cell RNA sequencing with both cross-sectional and longitudinal samples to assess how human CD8+ T cell heterogeneity and transcriptomes changed over nine decades of life.
[Nature Communications] |
|
|
|
| Researchers showed neutrophils undergoing NETosis and confirm expression markers of neutrophil extracellular traps (NETs) in vaccine-induced immune thrombotic thrombocytopenia patients.
[Nature Communications] |
|
|
|
| Investigators observed lower FcRγ protein expression in NK cell subsets from lung transplant patients during rapamycin treatment, suggesting a link with reduced mTOR activity.
[Journal of Experimental Medicine] |
|
|
|
| Scientists demonstrated that recipient sphingosine kinase 1 (Sphk1), but not Sphk2, was required for optimal sphingosine-1-phosphate receptor 1 (S1PR1)-dependent donor T cell allogeneic responses by secreting S1P.
[Cellular & Molecular Immunology] |
|
|
|
| Investigators used a glycan microarray with over 800 different components to screen a panel of 516 human monoclonal antibodies that had been randomly cloned from different B cell subsets originating from healthy human subjects.
[Journal of Biological Chemistry] |
|
|
|
| Researchers evaluated a novel telomerase-targeting therapeutic cancer vaccine, UV1, in combination with ipilimumab, in patients with metastatic melanoma.
[Journal of Translational Medicine] |
|
|
|
| Scientists developed an autologous humanized mouse cancer model by engrafting NSG mice with patient-derived xenografts and infused matched peripheral blood mononuclear cells.
[PLoS One] |
|
|
|
| Researchers identified dysregulated transcriptional program in B cells that disrupted differentiation of naive B cells into anti-tumor plasma cells.
[Cell Reports Medicine] |
|
|
|
|
| Scientists discuss the current state of knowledge about what is known about how pathways bifurcate to activate NF-κB and IRF family members.
[Biochemical Pharmacology] |
|
|
|
| The authors discuss molecular mechanisms underlying immune γδ T cell activity in liver disease, including immune liver injury, viral hepatitis, cirrhosis, and hepatocellular carcinoma, and review γδ T cell-based clinical immunotherapeutic approaches.
[Journal of Leukocyte Biology] |
|
|
|
|
| Fresh Tracks Therapeutics, Inc. announced that it has initiated the multiple ascending dose portion of the ongoing Phase I clinical trial in Canada evaluating FRTX-02, the company’s lead drug candidate, in healthy adult subjects.
[Fresh Tracks Therapeutics, Inc. (Globe Newswire, Inc.)] |
|
|
|
| Marker Therapeutics, Inc. announced that the company has been awarded a $2 million grant from the US FDA Orphan Products Grants program to support its Phase II ARTEMIS trial of its lead multi-tumor-associated antigen T cell product candidate, MT-401, in patients with post-transplant acute myeloid leukemia (AML).
[Marker Therapeutics, Inc.] |
|
|
|
| The Federation of American Societies for Experimental Biology (FASEB) Excellence in Science Lifetime Achievement Award recognized that Arlene Sharpe’s influence in the field of immunology extends well beyond the lab through her passionate training and mentoring of the next generation of scientists.
[Federation of American Societies for Experimental Biology] |
|
|
|
|
| September 30, 2022
Clayton, Victoria, Australia |
|
|
|
|
|
| | Louisiana State University – Baton Rouge, Louisiana, United States |
|
|
|
| | Albert Einstein College of Medicine – Bronx, New York, United States |
|
|
|
| | Rutgers New Jersey Medical School – Rutgers, New Jersey, United States |
|
|
|
| | Boston University – Boston, Massachusetts, United States |
|
|
|
| | Gunderson Health System – La Crosse, Wisconsin, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
